Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01198002 · ClinicalTrials.gov registry record · Phase 3
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,041
- Enrollment target
NCT01198002 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,041 participants.
The verdict
NCT01198002, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,041 participants
- Enrollment target
Study Summary
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate. This study is comprised of 3 periods: Period 1: 52-week blinded treatment Period 2: additional 48-week unblinded treatment Period 3: 48-week post-treatment follow-up
Interventions
- DRUG Methotrexate
- DRUG LY2127399
- DRUG Placebo Q4W
- DRUG Placebo Q2W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,041 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01198002
The ClinicalTrials.gov registry entry for NCT01198002 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,041 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methotrexate is the first listed.
NCT01198002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01198002 about?
NCT01198002 is a clinical study titled "A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate". The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate. This study is comprised of 3 periods: Period 1: 52-week blinded treatment Period 2: additional 48-week unblinded treatme...
What is the current status of trial NCT01198002?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,041 participants. The study started on 2010-12. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01198002?
The interventions under investigation include: Methotrexate (DRUG), LY2127399 (DRUG), Placebo Q4W (DRUG), Placebo Q2W (DRUG).
Who is sponsoring clinical trial NCT01198002?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.